Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Comment by commissionson May 06, 2004 10:44am

115 Views

Post# 7449931

RE: further thoughts

SS, we are on the same side here and both our comments echo the frustration of waiting for the US Investment Community to finely be onside and give AHX the valuation that it deserves.Lets wait it out and see what happens.If your right and I make an obscene amount of money I don't really care and vice versa as long as it ends up in a homerun. I am betting on the technology , leadership, and the GREED of the US BANKERS to make this work, I like my odds,you? Commissions

Bullboard Posts

Southern Ontario mineral processing operation receives green fund support